CN101472572B - Rar拮抗剂或反向激动剂在治疗化学疗法和/或放射疗法副作用中的用途 - Google Patents

Rar拮抗剂或反向激动剂在治疗化学疗法和/或放射疗法副作用中的用途 Download PDF

Info

Publication number
CN101472572B
CN101472572B CN2007800222950A CN200780022295A CN101472572B CN 101472572 B CN101472572 B CN 101472572B CN 2007800222950 A CN2007800222950 A CN 2007800222950A CN 200780022295 A CN200780022295 A CN 200780022295A CN 101472572 B CN101472572 B CN 101472572B
Authority
CN
China
Prior art keywords
chemotherapy
vtp
rar
alkyl
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800222950A
Other languages
English (en)
Chinese (zh)
Other versions
CN101472572A (zh
Inventor
R·A·钱德拉拉特纳
Y·袁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Link Pharmaceuticals
IO Therapeutics Inc
Original Assignee
IO Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IO Therapeutics Inc filed Critical IO Therapeutics Inc
Publication of CN101472572A publication Critical patent/CN101472572A/zh
Application granted granted Critical
Publication of CN101472572B publication Critical patent/CN101472572B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2007800222950A 2006-05-16 2007-05-16 Rar拮抗剂或反向激动剂在治疗化学疗法和/或放射疗法副作用中的用途 Expired - Fee Related CN101472572B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80077306P 2006-05-16 2006-05-16
US60/800,773 2006-05-16
PCT/US2007/011730 WO2007136653A2 (en) 2006-05-16 2007-05-16 Use of a rar antagonist or inverse agonist for the treatment of chemotherapy and/or radiation therapy side effects

Publications (2)

Publication Number Publication Date
CN101472572A CN101472572A (zh) 2009-07-01
CN101472572B true CN101472572B (zh) 2012-10-10

Family

ID=38566762

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800222950A Expired - Fee Related CN101472572B (zh) 2006-05-16 2007-05-16 Rar拮抗剂或反向激动剂在治疗化学疗法和/或放射疗法副作用中的用途

Country Status (9)

Country Link
US (1) US9271946B2 (enExample)
EP (1) EP2026778B1 (enExample)
JP (1) JP2009537540A (enExample)
CN (1) CN101472572B (enExample)
CA (1) CA2651487A1 (enExample)
DK (1) DK2026778T3 (enExample)
ES (1) ES2702128T3 (enExample)
TR (1) TR201819157T4 (enExample)
WO (1) WO2007136653A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013004685B1 (pt) 2010-09-01 2021-09-21 Thomas Jefferson University Uso de um agonista de receptor gama de ácido retinóico (rar?) para reparação e regeneração muscular
EP2858636B1 (en) * 2012-06-07 2018-09-05 Childrens Hospital Los Angeles Methods for treating neutropenia using retinoid agonists
CA2890424C (en) 2012-11-08 2020-11-17 Yamaguchi University Therapeutic agent for keratoconjunctive disorders
WO2014110165A1 (en) * 2013-01-08 2014-07-17 Io Therapeutics, Inc. Treatment of graft-versus-host disease disorders using rar antagonists
EP3000466B1 (en) 2013-05-22 2018-08-15 Yamaguchi University Inhibitor for retinochoroidal disorders
CN106413701A (zh) 2014-02-18 2017-02-15 洛杉矶儿童医院 用于治疗中性粒细胞减少症的组合物和方法
PL3380086T3 (pl) 2015-11-25 2022-02-21 Io Therapeutics, Inc. Oporne na cyp26 agonisty selektywne względem rar-alfa w leczeniu nowotworu
WO2017201200A1 (en) * 2016-05-19 2017-11-23 Orphagen Pharmaceuticals, Inc. Therapeutic compositions containing rar-alpha antagonists
EP3468554B1 (en) 2016-06-08 2023-08-09 Clementia Pharmaceuticals Inc. Methods for treating heterotopic ossification
CA3026563C (en) 2016-06-10 2023-11-28 Io Therapeutics, Inc. Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy
JP7018957B2 (ja) 2016-11-16 2022-02-14 クレメンティア ファーマシューティカルズ インコーポレイテッド 多発性骨軟骨腫（ｍｏ）を処置するための方法
EP3651757A4 (en) * 2017-07-13 2021-08-25 IO Therapeutics, Inc. RECEPTOR SUB-TYPE AND SELECTIVE RETINOID AND REXINOID COMPOUNDS FOR A FUNCTION IN COMBINATION WITH IMMUNE MODULATORS FOR ANTI-CANCER IMMUNOTHERAPY
AU2018326617B2 (en) 2017-08-31 2022-12-01 Io Therapeutics, Inc. Rar selective agonists in combination with immune modulators for cancer immunotherapy
CN113207799B (zh) * 2021-03-19 2022-03-15 中山大学 一种二型糖尿病小鼠快速心衰模型的构建方法
CN115974860B (zh) * 2022-12-15 2024-09-24 复旦大学附属中山医院 维甲酸类化合物及其制备方法和用途、含该化合物的药物组合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003078567A2 (en) * 2002-03-18 2003-09-25 Gamida-Cell Ltd. Methods of inducing differentiation in ex vivo expanded stem cells
CN1507355A (zh) * 2001-05-08 2004-06-23 Ĭ��ר�����޹�˾ 使用抗egfr抗体和抗激素剂的联合疗法
CN1659132A (zh) * 2002-06-04 2005-08-24 盖尔德马研究及发展公司 作为rar受体抑制剂的新型配体,制备它们的方法及其在人药物和化妆品方面的用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2102195T3 (es) 1992-12-28 1997-07-16 Eisai Co Ltd Derivados heterociclicos de acido carbonico que se fijan en receptores de retinoides.
US6008204A (en) * 1995-09-01 1999-12-28 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5958954A (en) 1995-09-01 1999-09-28 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5776699A (en) 1995-09-01 1998-07-07 Allergan, Inc. Method of identifying negative hormone and/or antagonist activities
US5952345A (en) 1995-09-01 1999-09-14 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US6218128B1 (en) 1997-09-12 2001-04-17 Allergan Sales, Inc. Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities
US6942980B1 (en) 1995-09-01 2005-09-13 Allergan, Inc. Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities
US20030219832A1 (en) 1996-03-11 2003-11-27 Klein Elliott S. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5877207A (en) 1996-03-11 1999-03-02 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US6555690B2 (en) 1996-06-21 2003-04-29 Allergan, Inc. Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5773594A (en) 1996-06-21 1998-06-30 Allergan Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5763635A (en) 1996-06-21 1998-06-09 Allergan Tetrahydronaphthalene derivatives substituted in the 8 position with alkyhidene groups having retinoid and/or retinoid antagonist-like biological activity
US5739338A (en) 1996-11-05 1998-04-14 Allergan N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity
US5728846A (en) 1996-12-12 1998-03-17 Allergan Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives
US6037488A (en) 1997-04-19 2000-03-14 Allergan Sales, Inc. Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US6521641B1 (en) 1998-10-08 2003-02-18 Allergan, Inc. Male anti-fertility agents
US6043381A (en) 1999-05-07 2000-03-28 Allergan Sales, Inc. Process for preparing substituted benzo[1,2-g]-chrom-3-ene, benzo[1,2-g]-thiochrom-3-ene and benzo[1,2-g]-1,2-dihydroquinoline derivatives
US6313168B1 (en) 1999-12-15 2001-11-06 Allergan Sales, Inc. Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
US20020193403A1 (en) 2001-05-03 2002-12-19 Allergan Sales, Inc. Methods of treating hyperlipidemia
IL152904A0 (en) * 2002-01-24 2003-06-24 Gamida Cell Ltd Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
US7105566B2 (en) * 2002-10-22 2006-09-12 Allergan, Inc. Methods of treatment during vascular procedures
AU2003298239A1 (en) * 2002-11-18 2004-06-15 Galderma Research And Development, S.N.C. Novel ligands that are antagonists of raf receptors, process for preparing them and use thereof in human medicine and in cosmetics

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1507355A (zh) * 2001-05-08 2004-06-23 Ĭ��ר�����޹�˾ 使用抗egfr抗体和抗激素剂的联合疗法
WO2003078567A2 (en) * 2002-03-18 2003-09-25 Gamida-Cell Ltd. Methods of inducing differentiation in ex vivo expanded stem cells
CN1659132A (zh) * 2002-06-04 2005-08-24 盖尔德马研究及发展公司 作为rar受体抑制剂的新型配体,制备它们的方法及其在人药物和化妆品方面的用途

Also Published As

Publication number Publication date
TR201819157T4 (tr) 2019-01-21
CN101472572A (zh) 2009-07-01
ES2702128T3 (es) 2019-02-27
WO2007136653A3 (en) 2008-07-03
DK2026778T3 (en) 2019-01-07
US20090176862A1 (en) 2009-07-09
WO2007136653A2 (en) 2007-11-29
JP2009537540A (ja) 2009-10-29
EP2026778A2 (en) 2009-02-25
CA2651487A1 (en) 2007-11-29
EP2026778B1 (en) 2018-11-14
US9271946B2 (en) 2016-03-01

Similar Documents

Publication Publication Date Title
CN101472572B (zh) Rar拮抗剂或反向激动剂在治疗化学疗法和/或放射疗法副作用中的用途
KR102164567B1 (ko) 염증 질환의 예방 및 치료
JP2002511411A (ja) 抗炎症剤
JPWO2004082715A1 (ja) 炎症性腸疾患治療剤としての併用医薬
JP2009504788A (ja) 化学療法の強化方法
JP2022116304A (ja) 血液がんの治療のためのＰＰＡＲγアゴニスト
WO2000038785A2 (en) Methods for treating certain diseases using naaladase inhibitors
KR20180107261A (ko) Myc 조정제로서의 MAX 결합제 및 그의 용도
CN107206053B (zh) 用于治疗血细胞减少症或减少血细胞减少症的持续时间的佛波醇酯组合物和方法
WO2011105611A1 (ja) 悪液質を治療するためのグレリン受容体作動物質
CN102341110B (zh) 用于减轻与化疗有关的副作用的维生素d3及其类似物
CN112930337B (zh) 抗增殖活性的苯氧基(杂)芳基醚
JPH11222440A (ja) 白血球減少症の予防剤および治療剤
EP4375278A1 (en) Immunoregulatory amide derivative with improved material properties
JPH02121923A (ja) ４―キノリンカルボン酸誘導体とインターロイキン―２の同時投与による哺乳動物のガン治療
CA3195137A1 (en) Substituted aromatic compounds and pharmaceutical compositions thereof
WO2022011554A1 (zh) 3-去氧-2-酮糖酸含氮衍生物及其制备方法和用途
JP2017066061A (ja) 円形脱毛症治療剤
WO2009142588A1 (en) Combination of (a) a chemokine receptor 1 (ccr1) antagonist and (b) glucocorticoid receptor modulator

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: NALKS PHARMACEUTICAL COMPANY

Free format text: FORMER OWNER: VITAE PHARMACEUTICALS INC.

Effective date: 20110113

Owner name: IO TREATMENT CO., LTD.

Free format text: FORMER OWNER: NALKS PHARMACEUTICAL COMPANY

Effective date: 20110113

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: PENNSYLVANIA STATE, USA TO: CALIFORNIA STATE, USA

TA01 Transfer of patent application right

Effective date of registration: 20110113

Address after: California, USA

Applicant after: IO Therapeutics, Inc.

Address before: California, USA

Applicant before: Link pharmaceuticals

Effective date of registration: 20110113

Address after: California, USA

Applicant after: Link pharmaceuticals

Address before: American Pennsylvania

Applicant before: VITAE PHARMACEUTICALS, Inc.

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20121010

CF01 Termination of patent right due to non-payment of annual fee